Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
13-58/No data
Plasma Protein Binding %
60-90
Volume Of Distribution L/Kg
3-6
Dose For Normal Renal Function
2.5-10 mg q6-8h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50-75% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None
Supplement For Dialysis [Recommendation Level]: Pd
PD: None
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, titrate, [D]
References
Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci. 1995; 245: 114-24. [PMID: 7654787] / Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther. 1987; 41: 392-401. [PMID: 3829576] / Quinn DI, Wodak A, Day RO. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet. 1997; 33: 344-400. [PMID: 9391747] / Sö we J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet. 1986; 11: 87-106. [PMID: 3514045]